Core Viewpoint - Green Leaf Pharmaceutical (02186.HK) announced the successful inclusion of five new products in the National Medical Insurance Drug List (2025) and the Commercial Health Insurance Innovative Drug List (2025) [1] Group 1: New Product Inclusion - The five new products include: - Mimesin (Oxycodone Naloxone Extended-Release Tablets) and Ruibailai (Paliperidone Palmitate Injection (II)) are newly included in the National Medical Insurance Drug List - Zanbija (Injectable Lurbinectedin) is successfully included in the Commercial Health Insurance Innovative Drug List - Baituo Wei (Injectable Goserelin Microspheres) and Ruiketuo (Injectable Risperidone Microspheres (II)) have successfully renewed their inclusion in the National Medical Insurance Drug List [1][1][1] Group 2: Strategic Importance - The company believes that the synergy between medical insurance and commercial insurance is a significant measure to support the high-quality development of innovative drugs, promoting basic healthcare and innovation [1] - The inclusion of these five products through multiple access pathways into a multi-tiered medical security system will enhance drug accessibility for patients in related disease areas, effectively reducing their treatment burden [1][1] - This strategic move is expected to accelerate market penetration and coverage of these products, laying a solid foundation for their long-term high-quality growth [1][1]
绿叶制药(02186.HK)：集团五款新产品成功纳入2025年国家医保药品目录或商保创新药目录